Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common sedative boost survival after cancer surgery in seniors?

NCT ID NCT03012971

Disease control Sponsor: Peking University First Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jul 29, 2026 · Updated 3 times

Summary

This study looked at whether adding dexmedetomidine to standard morphine pain relief after cancer surgery helps elderly patients (65-90 years) live longer. 1,500 participants were randomly assigned to receive either morphine alone or morphine plus dexmedetomidine for three days after surgery. The goal was to see if the combination improves overall survival and reduces cancer recurrence by easing stress and inflammation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
dexmedetomidine
What this could lead to
If it works, this could improve survival and reduce cancer recurrence in elderly patients after surgery.
What could go wrong
This is a completed trial, but results may not show a clear benefit. The effect on survival is uncertain and may not apply to all cancer types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

1,500 people

The number who actually took part.

Started

Jan 2017

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

65 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age \>= 65 years, \< 90 years; * Scheduled to undergo curative resection for primary solid organ cancer under general anesthesia, with an expected duration of surgery \>=2 hours; * Planned to use patient-controlled intravenous analgesia after surgery; * Provide written informed consent. Exclusion Criteria: * Preoperative history of schizophrenia, epilepsy, parkinsonism or myasthenia gravis; * Preoperative radio- or chemotherapy; * Inability to communicate in the preoperative period because of coma, profound dementia or language barrier; * Preoperative obstructive sleep apnea (previously diagnosed as obstructive sleep apnea, or a STOP-Bang score \>= 3 and serum HCO3- \>= 28 mmol/L); * Brain trauma or neurosurgery; * Preoperative left ventricular ejection fraction \< 30%, sick sinus syndrome, severe sinus bradycardia (\< 50 beats per minute), or second-degree or above atrioventricular block without pacemaker; * Severe hepatic dysfunction (Child-Pugh class C) or severe renal dysfunction (requirement of renal replacement therapy before surgery); * ASA classification \>= IV.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Analgesia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

agnosia cancer pain agnosia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Analgesia Dexmedetomidine Elderly Long-term outcome Surgery

Contacts and locations

Locations

  • Affiliated Hospital of Hebei University

    Baoding, Hebei, 050031, China

  • Chongqing University Fuling Hospital

    Chongqing, Chongqing Municipality, 408099, China

  • Guizhou Provincial People's Hospital , China, Contact:

    Guiyang, Guizhou, 550002, China

  • Peking University First Hospital

    Beijing, Beijing Municipality, 100034, China

  • Peking University International Hospital , , China, Contact:

    Beijing, Beijing Municipality, 102206, China

  • Qingdao Municipal Hospital , , China, Contact:

    Qingdao, Shandong, 266011, China

  • Shanxi Provincial Cancer Hospital , China, Contact:

    Taiyuan, Shanxi, 030013, China

  • The Second Affiliated Hospital of Air Force Medical University

    Xi'an, Shaanxi, 710038, China

  • The Third Central Hospital of Tianjin

    Tianjin, Tianjin Municipality, 300170, China

  • The Third Xiangya Hospital of Central South University

    Changsha, Hunan, 410013, China

  • Tianjin Hospital of ITCWM-Nankai Hospital

    Tianjin, Tianjin Municipality, 300100, China

  • Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Beijing, Beijing Municipality, 100091, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.